Ten years since the immune checkpoint inhibitor ipilimumab was approved for advanced
melanoma, it is time to reflect on the lessons learned regarding modulation of the immune …

Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

Fecal microbiota transplantation (FMT) represents a potential strategy to overcome
resistance to immune checkpoint inhibitors in patients with refractory melanoma; however …

PURPOSE Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4–
blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in …

PURPOSE We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus
ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic …

Cancer immunotherapies, including adoptive T cell transfer, can be ineffective because
tumors evolve to display antigen-loss-variant clones. Therapies that activate multiple …

Patients with resected stage IIB/C melanoma have high recurrence risk, similar to those with
resected stage IIIA/B disease. The phase 3, double-blind CheckMate 76K trial assessed 790 …

High serum lactate dehydrogenase (LDH) levels are typically associated with a poor
prognosis in many cancer types. Even the most effective drugs, which have radically …

Abstract Chaperone-mediated autophagy (CMA), a proteolytic system contributing to the
degradation of intracellular proteins in lysosomes, is upregulated in tumors for pro …

Background The IMMUNED trial previously showed significant improvements in recurrence-
free survival for adjuvant nivolumab plus ipilimumab as well as for adjuvant nivolumab alone …